Cited by 101T-cell and B-cell ImmunologyGenomics and Chromatin DynamicsDevelopmental Biology and Gene Regulation

The DOI matches its Crossref record; 163 of the 228 references it cites were found in a registry or an index; 189 of the 244 sources its claims cite were checked for support.

Mechanisms of Action of Hematopoietic Transcription Factor PU.1 in Initiation of T-Cell Development

Open access

Abstract

PU.1 is an ETS-family transcription factor that plays a broad range of roles in hematopoiesis. A direct regulator of myeloid, dendritic-cell, and B cell functional programs, and a well-known antagonist of terminal erythroid cell differentiation, it is also expressed in the earliest stages of T-cell development of each cohort of intrathymic pro-T cells. Its expression in this context appears to give T-cell precursors initial, transient access to myeloid and dendritic cell developmental competence and therefore to represent a source of antagonism or delay of T-cell lineage commitment. However, it has remained uncertain until recently why T-cell development is also intensely dependent upon PU.1. Here, we review recent work that sheds light on the molecular biology of PU.1 action across the genome in pro-T cells and identifies the genes that depend on PU.1 for their correct regulation. This work indicates modes of chromatin engagement, pioneering, and cofactor recruitment ("coregulator theft") by PU.1 as well as gene network interactions that not only affect specific target genes but also have system-wide regulatory consequences, amplifying the impact of PU.1 beyond its own direct binding targets. The genes directly regulated by PU.1 also suggest a far-reaching transformation of cell biology and signaling potential between the early stages of T-cell development when PU.1 is expressed and when it is silenced. These cell-biological functions can be important to distinguish fetal from adult T-cell development and have the potential to illuminate aspects of thymic function that have so far remained the most mysterious.

Overview

AI snapshot

Written from the paper’s full text.

TL;DR

PU.1 is transiently expressed in early pro-T cells, where it acts as a pioneer/cofactor-redistributing transcription factor that supports proliferation, delays commitment, and maintains a myeloid/dendritic-competence window constrained by Notch signaling. Its role is ontogenically scaled: largely dispensable in first-wave fetal T cells but important for later fetal and adult T-cell development.

Key findings

  • PU.1 binds >30,000 genomic sites in the earliest pro-T cells, declining to ~5,000 sites by T-lineage commitment; its motifs are highly enriched at chromatin sites that lose accessibility during commitment, and acute PU.1 deletion leaves many of these sites less open.
  • Within the T-cell pathway, PU.1 slows differentiation while supporting proliferation: PU.1-disrupted precursors underwent fewer cycles and a larger fraction progressed to DN3 over the same absolute time; high-confidence targets include activated genes such as Mef2c, Lmo2, Bcl11a, and Hhex, and repressed genes such as E2f2.
  • PU.1 directly regulates many signaling/cell-biology genes—cytokine receptors, chemokine receptors, tyrosine kinases, G-protein-coupled receptors, adhesion and cytoskeletal molecules—more than transcription factor genes, and can repress indirectly by “coregulator theft,” redistributing Runx1 and Satb1 away from other functional sites.
  • Ontogeny: first-wave fetal T cells tolerate ~5-fold reduced PU.1 almost unchanged, whereas later fetal hematopoietic stem/progenitor cells show severe T-cell defects; the PU.1 phase lasts >10 days in young adult thymocytes but may last only 1–2 days in many first-wave fetal thymocytes.

Methods

  • Review/synthesis of recent mouse T-cell development studies, mostly postnatal thymus or late fetal progenitors, using primary pro-T cells, OP9-DL1/DL4 stromal co-cultures, and the Scid.adh.2C2 pro-T-like cell line.
  • Gain- and loss-of-function perturbations: retroviral PU.1 overexpression, Cre-mediated Spi1 deletion, Cas9/sgRNA Spi1 disruption, and dominant-negative PU.1-ENG; readouts include ChIP-seq, ATAC-seq, transcriptome, proteomics, and GO/PANTHER pathway analyses.
  • High-confidence PU.1 target genes were defined as those showing reciprocal responses in gain- and loss-of-function perturbations within the DN2a–DN2b developmental interval.

Limitations

  • Stated: biochemical mechanisms of PU.1/Notch effects remain to be fully defined; PU.1 small-molecule inhibitors have not yet been tested in normal T-cell development; long PU.1 protein half-life and asynchronous deletion make loss-of-function effects weak at <2 days and confounded by developmental progression at later timepoints.
  • Stated: gain-of-function overexpression can inhibit Notch signaling and produce nonlinear, switch-like transdifferentiation, so some effects may be high-dose artifacts; Scid.adh.2C2 cells do not fully restore the ETP/DN2a chromatin landscape.
  • Evident: the review is largely based on mouse systems and in vitro cultures, which the authors note may lack normal thymic environmental molecules; PU.1-high early stages are rare and difficult to study directly in vivo.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fimmu.2019.00228

Cites

163 of 163 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Schematic of T-cell development in the thymus. Major landmarks for T cell developmental stages are CD4 and CD8. CD4− CD8−: “DN”; CD4+ CD8+: “DP,” CD4+ CD8−: “CD4SP”; CD4− CD8+: “CD8SP.” All events described in this review occur within the DN stages, which are divided by other markers. ETP: Kit++ CD44+ CD25−; DN2a: Kit++ CD44+ CD25+; DN2b: Kit+ CD44+ CD25+; DN3a: Kit− CD44− CD25+ CD28−; DN3b: Kit− CD44− CD25+ CD28+; DN4: Kit− CD44− CD25− CD28+. Stages up through DN3a do not depend on T-cell receptor gene rearrangement status and are called “Pro-T cells.” Many cell cycles occur between the ETP stage and commitment, more in post-natal T cell development and fewer in fetal T-cell development. The trends in PU.1 expression, the timing of intrinsic cell commitment to the T-cell lineage, and the stages that depend on Notch signaling from the thymic microenvironment are shown. Gray or blue regions depict thymic cortex. Lighter region depicts thymic medulla, where final maturation of developing T cells takes place. CD4SP: maturing T helper cells. CD8SP: maturing T cytotoxic cells. Treg: thymically derived regulatory T cells. iNKT: Natural Killer T cells with invariant T cell receptors [Schematic adapted from Rothenberg et al. (34)].
Figure 1 Schematic of T-cell development in the thymus. Major landmarks for T cell developmental stages are CD4 and CD8. CD4− CD8−: “DN”; CD4+ CD8+: “DP,” CD4+ CD8−: “CD4SP”; CD4− CD8+: “CD8SP.” All events described in this review occur within the DN stages, which are divided by other markers. ETP: Kit++ CD44+ CD25−; DN2a: Kit++ CD44+ CD25+; DN2b: Kit+ CD44+ CD25+; DN3a: Kit− CD44− CD25+ CD28−; DN3b: Kit− CD44− CD25+ CD28+; DN4: Kit− CD44− CD25− CD28+. Stages up through DN3a do not depend on T-cell receptor gene rearrangement status and are called “Pro-T cells.” Many cell cycles occur between the ETP stage and commitment, more in post-natal T cell development and fewer in fetal T-cell development. The trends in PU.1 expression, the timing of intrinsic cell commitment to the T-cell lineage, and the stages that depend on Notch signaling from the thymic microenvironment are shown. Gray or blue regions depict thymic cortex. Lighter region depicts thymic medulla, where final maturation of developing T cells takes place. CD4SP: maturing T helper cells. CD8SP: maturing T cytotoxic cells. Treg: thymically derived regulatory T cells. iNKT: Natural Killer T cells with invariant T cell receptors [Schematic adapted from Rothenberg et al. (34)].CC BY · PubMed Central
Figure 2 Framework for experimental perturbation studies to define functions of PU.1 in early thymic development. Stages of cells are as in Figure 1 (DN3: primarily DN3a). Exogenous PU.1 is added by retroviral transduction. Note the dependence of the PU.1 functions tested upon the timing of the experimental perturbation. Endogenous PU.1 can be deleted by Cas9 plus single-chain guide RNAs (sgRNA) against Spi1, or by introducing Cre into cells with floxed Spi1 alleles. PU.1 can also be neutralized by adding a dominant negative construct. The DN2a-DN2b interval is accessible to experimental perturbation. The approximate developmental stage represented by the Scid.adh.2C2 cell line (see text) is also shown [Schematic adapted from Ungerbäck et al. (85)].
Figure 2 Framework for experimental perturbation studies to define functions of PU.1 in early thymic development. Stages of cells are as in Figure 1 (DN3: primarily DN3a). Exogenous PU.1 is added by retroviral transduction. Note the dependence of the PU.1 functions tested upon the timing of the experimental perturbation. Endogenous PU.1 can be deleted by Cas9 plus single-chain guide RNAs (sgRNA) against Spi1, or by introducing Cre into cells with floxed Spi1 alleles. PU.1 can also be neutralized by adding a dominant negative construct. The DN2a-DN2b interval is accessible to experimental perturbation. The approximate developmental stage represented by the Scid.adh.2C2 cell line (see text) is also shown [Schematic adapted from Ungerbäck et al. (85)].CC BY · PubMed Central
Figure 3 PU.1 and Notch collectively determine T vs. myeloid lineage fates. (A) Notch signaling within the thymus normally constrains PU.1 effects to support early pro-T cell development while blocking alternative fates that PU.1 would otherwise promote. Notch signaling itself does not repress PU.1 expression; however, other transcription factors induced by Notch signaling eventually silence expression of Spi1 during the DN2b stage. (B) Separation of the effects of PU.1 within the T-cell pathway from effects of PU.1 to promote lineage deviation, in PU.1 gain of function experiments. A fraction of cells expressing high levels of PU.1 shift to a myeloid-like state that can be phenotypically distinguished from cells remaining within the T-cell state. This distinction is necessary to relate gain-of-function effects of PU.1 in pro-T cells to effects of loss of endogenous PU.1 in perturbation experiments. Lineage deviation is associated with a broad loss of Notch signal response in the cells, suggesting that the constraint mechanism shown in A has been overwhelmed in these cells. Biochemical mechanisms of these effects remain to be fully defined. Schematic in A, adapted from (58); in B, adapted from (85).
Figure 3 PU.1 and Notch collectively determine T vs. myeloid lineage fates. (A) Notch signaling within the thymus normally constrains PU.1 effects to support early pro-T cell development while blocking alternative fates that PU.1 would otherwise promote. Notch signaling itself does not repress PU.1 expression; however, other transcription factors induced by Notch signaling eventually silence expression of Spi1 during the DN2b stage. (B) Separation of the effects of PU.1 within the T-cell pathway from effects of PU.1 to promote lineage deviation, in PU.1 gain of function experiments. A fraction of cells expressing high levels of PU.1 shift to a myeloid-like state that can be phenotypically distinguished from cells remaining within the T-cell state. This distinction is necessary to relate gain-of-function effects of PU.1 in pro-T cells to effects of loss of endogenous PU.1 in perturbation experiments. Lineage deviation is associated with a broad loss of Notch signal response in the cells, suggesting that the constraint mechanism shown in A has been overwhelmed in these cells. Biochemical mechanisms of these effects remain to be fully defined. Schematic in A, adapted from (58); in B, adapted from (85).CC BY · PubMed Central
Figure 4 Profound changes in regulatory gene expression distinguish PU.1-induced lineage deviation from PU.1 effects within the T-cell pathway. Charts show changes in expression of the indicated genes (log2 Fold Change relative to controls) induced by introduction of PU.1 into post-commitment pro-T cells (DN2b-DN3). Panels compare effects on T-lineage regulatory genes (top) and non-T regulatory and signaling genes (bottom) between cells remaining within the T-lineage pathway (light blue bars) and cells undergoing lineage deviation (dark blue bars). Light, dark red bars show corresponding measured levels of exogenous PU.1 in these samples, as log2 fold changes over controls, which have downregulated most of their endogenous PU.1 expression at this stage. Results are from Ungerbäck et al. (85).
Figure 4 Profound changes in regulatory gene expression distinguish PU.1-induced lineage deviation from PU.1 effects within the T-cell pathway. Charts show changes in expression of the indicated genes (log2 Fold Change relative to controls) induced by introduction of PU.1 into post-commitment pro-T cells (DN2b-DN3). Panels compare effects on T-lineage regulatory genes (top) and non-T regulatory and signaling genes (bottom) between cells remaining within the T-lineage pathway (light blue bars) and cells undergoing lineage deviation (dark blue bars). Light, dark red bars show corresponding measured levels of exogenous PU.1 in these samples, as log2 fold changes over controls, which have downregulated most of their endogenous PU.1 expression at this stage. Results are from Ungerbäck et al. (85).CC BY · PubMed Central
Figure 5 PU.1 structure and derivatives of PU.1 used for functional analysis. Domain boundaries within the amino acid sequence of murine PU.1 are depicted with their associated functions indicated at the top (4, 18, 90, 91). Epitope-tagged wildtype PU.1 (PU1WTHA) and two epitope-tagged, modified constructs are shown (PU1ENGHA, PU1ETSHA); these are used to interrupt endogenous PU.1 activity (79, 82). PU1ENGHA and PU1ETSHA have a full DNA binding domain and efficiently enter open chromatin, but are deficient in entering closed chromatin (85). DE: Acidic residue-rich transactivation domain. Q: Glutamine-rich transactivation domain. PEST: Proline, Glutamate, Serine and Threonine-rich domain, site of IRF4 and IRF8 interaction (interx). Note that in PU.1 this “PEST” domain does not make the protein unstable. ETS: E-twenty-six proto-oncogene homology domain, the DNA binding domain of PU.1. This is also the region that interacts with basic leucine zipper (bZIP) factors such as Jun and C/EBP factors, and GATA family factors.
Figure 5 PU.1 structure and derivatives of PU.1 used for functional analysis. Domain boundaries within the amino acid sequence of murine PU.1 are depicted with their associated functions indicated at the top (4, 18, 90, 91). Epitope-tagged wildtype PU.1 (PU1WTHA) and two epitope-tagged, modified constructs are shown (PU1ENGHA, PU1ETSHA); these are used to interrupt endogenous PU.1 activity (79, 82). PU1ENGHA and PU1ETSHA have a full DNA binding domain and efficiently enter open chromatin, but are deficient in entering closed chromatin (85). DE: Acidic residue-rich transactivation domain. Q: Glutamine-rich transactivation domain. PEST: Proline, Glutamate, Serine and Threonine-rich domain, site of IRF4 and IRF8 interaction (interx). Note that in PU.1 this “PEST” domain does not make the protein unstable. ETS: E-twenty-six proto-oncogene homology domain, the DNA binding domain of PU.1. This is also the region that interacts with basic leucine zipper (bZIP) factors such as Jun and C/EBP factors, and GATA family factors.CC BY · PubMed Central
Figure 6 Summary of PU.1 binding features in pro-T cells. (1) PU.1 binding is preferentially retained at high-affinity sites as pro-T cells progressively reduce their PU.1 levels. This feature indicates that PU.1 primarily uses mass action (concentration × affinity) to determine its genomic site choices in these cells. (2) PU.1 works as a positive regulator in pro-T cells primarily by binding and controlling accessibility of sites distal to the transcriptional start sites, not at promoters. (3) The binding profiles of full-length PU.1 (PU1WT) show a tradeoff between binding site affinity and binding site accessibility in chromatin; however, constructs with the PU.1 DNA binding domain but lacking the transactivation domains (PU1 DBD) are poor at engaging sites in closed chromatin no matter how high their potential affinities.
Figure 6 Summary of PU.1 binding features in pro-T cells. (1) PU.1 binding is preferentially retained at high-affinity sites as pro-T cells progressively reduce their PU.1 levels. This feature indicates that PU.1 primarily uses mass action (concentration × affinity) to determine its genomic site choices in these cells. (2) PU.1 works as a positive regulator in pro-T cells primarily by binding and controlling accessibility of sites distal to the transcriptional start sites, not at promoters. (3) The binding profiles of full-length PU.1 (PU1WT) show a tradeoff between binding site affinity and binding site accessibility in chromatin; however, constructs with the PU.1 DNA binding domain but lacking the transactivation domains (PU1 DBD) are poor at engaging sites in closed chromatin no matter how high their potential affinities.CC BY · PubMed Central
Figure 7 Repression by PU.1 can be caused by redistribution of a limiting co-regulator (co-regulator theft). Schematic depicts the complementary changes in factor binding patterns as well as in transcriptional activity of genes that are normally PU.1-dependent (right) or PU.1-inhibited (left), across the developmental stages when PU.1 goes from high to low (top) and then in an experimental condition when PU.1 is re-introduced into committed cells that have already turned off endogenous PU.1 (bottom). The figure shows that the redistribution of partner factors Runx1 (R) and Satb1 (S) by recruitment to PU.1 (P) binding sites occurs at the expense of sites that these factors would otherwise occupy together with other T-cell factors (T). Broken-line arrows (lower left) indicate that redistribution probably involves the dynamic equilibrium of binding of these factors between genomic sites that are differentially preferred in the presence and absence of PU.1. In at least some cases, the “theft” of the cofactors also results in relative closing of the chromatin at sites from which these cofactors are removed. Schematic modified from Hosokawa et al. (80).
Figure 7 Repression by PU.1 can be caused by redistribution of a limiting co-regulator (co-regulator theft). Schematic depicts the complementary changes in factor binding patterns as well as in transcriptional activity of genes that are normally PU.1-dependent (right) or PU.1-inhibited (left), across the developmental stages when PU.1 goes from high to low (top) and then in an experimental condition when PU.1 is re-introduced into committed cells that have already turned off endogenous PU.1 (bottom). The figure shows that the redistribution of partner factors Runx1 (R) and Satb1 (S) by recruitment to PU.1 (P) binding sites occurs at the expense of sites that these factors would otherwise occupy together with other T-cell factors (T). Broken-line arrows (lower left) indicate that redistribution probably involves the dynamic equilibrium of binding of these factors between genomic sites that are differentially preferred in the presence and absence of PU.1. In at least some cases, the “theft” of the cofactors also results in relative closing of the chromatin at sites from which these cofactors are removed. Schematic modified from Hosokawa et al. (80).CC BY · PubMed Central
Figure 8 PU.1 globally regulates genes involved in multiple signaling and cell biological properties as well as other “phase 1” transcription factors across the stages when PU.1 is expressed. Summary of normal expression patterns of representative groups of PU.1 regulated genes is shown, illustrated using the ImmGen (119) (www.immgen.org) “My Gene Set” browser (http://rstats.immgen.org/MyGeneSet_New/index.html; Microarray V1). Natural levels of expression are shown in different “Stem and Progenitor” cell sets (120) (under light blue bar) and in successive stages of “αβ T cell” development (121) (under purple bar), where the color scale represents z score (warm colors, high expression; cold colors, low expression). Vertical line between “preT_DN2A_Th” and “preT_DN2B_Th” relates these stages to the timing of commitment, when PU.1 levels decline. (A) Genes encoding transcription factors activated by PU.1 in multiple tests (58, 79, 85). (B) Representative genes activated by PU.1 that encode tyrosine protein kinases, cytokine receptors, and G protein coupled receptors, from Table 1 [data from Ungerbäck et al. (85)]. (C) Genes activated by PU.1 that encode additional cell surface molecules, signaling receptors and adhesion molecules, from Table 1. (D) Genes repressed by PU.1, encoding chemokine receptors and G-protein coupled receptors, from Table 1. Functional clusters used in this summary were as defined by DAVID Gene Functional Classification tool (DAVID 6.8) (https://david.ncifcrf.gov/gene2gene.jsp).
Figure 8 PU.1 globally regulates genes involved in multiple signaling and cell biological properties as well as other “phase 1” transcription factors across the stages when PU.1 is expressed. Summary of normal expression patterns of representative groups of PU.1 regulated genes is shown, illustrated using the ImmGen (119) (www.immgen.org) “My Gene Set” browser (http://rstats.immgen.org/MyGeneSet_New/index.html; Microarray V1). Natural levels of expression are shown in different “Stem and Progenitor” cell sets (120) (under light blue bar) and in successive stages of “αβ T cell” development (121) (under purple bar), where the color scale represents z score (warm colors, high expression; cold colors, low expression). Vertical line between “preT_DN2A_Th” and “preT_DN2B_Th” relates these stages to the timing of commitment, when PU.1 levels decline. (A) Genes encoding transcription factors activated by PU.1 in multiple tests (58, 79, 85). (B) Representative genes activated by PU.1 that encode tyrosine protein kinases, cytokine receptors, and G protein coupled receptors, from Table 1 [data from Ungerbäck et al. (85)]. (C) Genes activated by PU.1 that encode additional cell surface molecules, signaling receptors and adhesion molecules, from Table 1. (D) Genes repressed by PU.1, encoding chemokine receptors and G-protein coupled receptors, from Table 1. Functional clusters used in this summary were as defined by DAVID Gene Functional Classification tool (DAVID 6.8) (https://david.ncifcrf.gov/gene2gene.jsp).CC BY · PubMed Central

Verification

Claims the paper makes

71 Partly supported · 54 Own interpretation · 39 Supported · 19 No basis given · 12 Own result · 7 No full text of the sources · 4 Mixed support · 3 Supported so far · 3 Own method · 2 Couldn’t confirm · 2 Not checked yet · 1 Not supported · accuracy not yet measured

Verify all 1 references — free account
  • It may state two separate claims as one. 80
  • Probably not a substantial claim. 19
94 of 94
  • The paper relies on this without support.

    Developmentally potent transcription factors often transform a cell's identity by positively or negatively regulating the expression of other transcription factors.

    “Developmentally potent transcription factors often transform a cell's identity by positively or negatively regulating the expression of other transcription factors.”
1 of 1

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 228 references

Research works printed but not linked: 1

  1. Petrovick, 1998, Multiple functional domains of AML1: PU, 3915

Cited by

Sorted by citations

See all 101

Metadata

Authors
Rothenberg, E. V., Hosokawa, H., & Ungerbäck, J.
Affiliations
California Institute of Technology (US)
Corresponding author
Rothenberg, Ellen V.
Venue
Frontiers in Immunology
Published
2019-02-20
Volume
10
Pages
228-228
ISSN
1664-3224 (ISSN-L)
OpenAlex
W2915813447
Cited by
99
References
228
Citations by year
2026: 11 · 2025: 16 · 2024: 15 · 2023: 16 · 2022: 9 · 2021: 16 · 2020: 9 · 2019: 7
FWCI
3.28
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (submittedVersion, cc-by)
  • PubMed Central (submittedVersion, cc-by)
  • CaltechAUTHORS (California Institute of Technology) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • U.S. Public Health Service (R01AI095943, R01HD076915)
  • Manpei Suzuki Diabetes Foundation
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
Keywords
PU.1, ETS transcription factors, T cell development, pro-T cells, T cell lineage commitment, coregulator recruitment, gene regulatory networks, thymus
MeSH terms
Proto-Oncogene Protein Spi-1, Animals, Cell Differentiation, Hematopoiesis, Humans, Proto-Oncogene Proteins, T-Lymphocytes, Transcription, Genetic, Trans-Activators, Hematopoietic Stem Cell Transplantation, Cell Lineage, Gene Regulatory Networks

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review